



Welcome to the DHI funding update!

In this file you will find **open and upcoming funding opportunities** for research related to health and health technology.

Follow the hyperlinks to get to the official website of the funding organization, NWO, ZonMw or EU website.

You can also choose from following options to facilitate our conversation:

Are you interested in any of the funding? Feel free to [contact me](#) to discuss your ideas and the match between the call and your plans! You can indicate this [HERE](#).

Are you currently writing a proposal? Feel free to [contact me](#) to discuss the project, matching to the call (e.g. requirements) and consortium.

Are you preparing NWA ORC pre-proposal (09.06.22)? Feel free to [contact me](#), at TUD I&IC we have a whole NWA-team to support your application and help you with Impact Outlook/Plan.

Are you preparing EU proposal for cluster 1 Health with the deadline in April 2022 e.g. together with Convergence partners? Feel free to [contact me](#), we can discuss your/ TUD role and how we can best contribute to the quality of the proposal.

Are you interested in what is coming up within EU cluster 1 Health calls for 2023-2024? Feel free to [contact me](#), and I can share with you draft work program will calls and topic descriptions.

Are you interested in personal grant: ERC grant? Feel free to [contact me](#) to discuss the idea, ERC characteristics and sign up for workshops we organize.

Are you interested in personal grant: VI-Veni, Vidi, Vici NWO/ZonMw? Feel free to contact TUD personal grant coordinator Nathasja Croon N.Croon@tudelft.nl, she will inform you about available training and redirect you to advisors.

Jaga Schreiber

Health Funding Advisor

TU Delft Innovation and Impact Centre

M +31 (0) 6 28362580, [call me via MS TEAMS](#)

j.k.schreiber@tudelft.nl

Contents

NL funding opportunities	2
Key enabling technologies for minimally invasive interventions in healthcare	2
Open Technology Programme 2022	3
Early detection of cancer - innovations for detection and diagnosis' KIC Demand-driven Partnership NWO –KWF Kankerbestrijding	4
Open Competition Domain Science - M	5
Open Competition Domain Science – XS (young talent!)	7
ZonMw Medicinale cannabis als behandeling bij kinderepilepsie - Medicinal cannabis as a treatment for childhood epilepsy	7
HTA methodologie - ronde 1: Methodologie voor waardebeoordeling van incrementeel ontwikkelende medische technologie (MedTech) HTA methodology - round 1: Methodology for Valuation of Incrementally Developing Medical Technology (MedTech).....	9
Pre-announcement funding round technologies to support therapy development COVID-19	10
EU calls (collaborative).....	11
JPI HDHL: “Nutrition-responsiveness of the immune system: interplay between infectious diseases and diet-related metabolic diseases and the potential for food-based solutions (NUTRIMMUNE)”	11
EIC Pathfinder Challenge: Cardiogenomics	12
EIC Pathfinder Challenge: Towards the Healthcare Continuum: technologies to support a radical shift from episodic to continuous healthcare	13
Foundations providing research funding	15

NL funding opportunities

[Key enabling technologies for minimally invasive interventions in healthcare](#)

Title	Key enabling technologies for minimally invasive interventions in healthcare			
DHI pillar	NeuroTech	OncoTech	CardioTech	Integrated Tech.
Funder	NWO			
Program	Knowledge and Innovation Covenant, Mission-driven calls (KIC 2020-2023), Key enabling technologies			
Aim of the call	Theme of this call concerns Key Enabling Technologies for minimally invasive interventions . In order to keep people healthy while ageing, it is mandatory that they are stimulated to keep professionally and/or socially actively participating in society. Precise and effective technology can support this on many levels. One of them is that it will affect and improve minimally invasive treatment. Effective interventions with minimal collateral damage will shorten the stay in hospital and the time that people are patients and inhibited to actively participate in society. Examples of such interventions include novel robotic-assisted approaches, new micromechanical surgical devices, catheter or needle-based interventions, image-guided interventions, therapies guided by sensors and actuators, interventions supported by augmented reality, and approaches using for example a sustainable design, e.g. reusable devices or new manufacturing principles . This Call for proposals invites consortia to submit a proposal for a research project that aims to support the transition from invasive to minimally invasive interventions with minimal collateral damage . Multidisciplinary collaboration within consortia composed of both clinical and			

	<p>technical experts is essential to achieve this goal. This call request projects in which new innovative technologies will be developed or in which new combinations of existing technologies are combined in an innovative way so that they are applicable in a clinical environment. Supporting (digital) technologies can also be developed in this call, as long as their peri-operative use will directly lead to less collateral damage from the minimally invasive intervention. Within this call, four Key Enabling Technologies have been identified as focus areas. Each project must use one or more of these key enabling technologies. Applicants are free to choose whether to incorporate them individually or combine two or more of them. The four Key Enabling Technologies are as follows:</p> <ul style="list-style-type: none"> •Robotics (KET 3-6) •Sensors & Actuators (KET 3-7) •Imaging Technologies (KET 4-1) •Integrated Photonics (KET 4-2) <p>For more information regarding these key enabling technologies, see https://www.hollandhightech.nl/kia-sleuteltechnologieen and 20190712 KIA-ST Bijlage A - Kennis- en innovatievragen.pdf (hollandhightech.nl).</p>
Applicants / consortium	consortium: Main applicant, Co-applicant(s), Co-funder(s), Collaborating partner(s), (external) Stakeholders
Budget	minimum of € 525,000 and maximum of € 1,250,000 in NWO funding can be applied for in this Call for proposals. With this, NWO will fund no more than 70% of the total project budget; Total budget for this call 5,5 mln
Co-funding	The co-funders jointly contribute a net minimum amount of 30% of the total budget for the proposal; may be provided entirely in cash and entirely in kind, without any requirements regarding the balance between these two components in a project proposal. In addition, the complete in-cash co-funding may be provided by both public and private parties. At least 50% of the total co-funding must be from private sources
Deadline	pre-proposals: 16 May 2022 full proposals: 27 September 2022
Link	https://www.nwo.nl/en/calls/key-enabling-technologies-minimally-invasive-interventions-healthcare
Other	'Key Enabling Technologies' (KET) is an umbrella term for technologies of the "future" that will have an enormous impact on how we live, learn, work and produce. These are technologies that will brush to one side our ideas about what is possible and could potentially lead to groundbreaking innovations. KET are characterised by their broad applicability and scope: they can be used in various sectors and/or innovations. KET are essential in solving societal challenges and/or have a major potential contribution to the economy. KET ensure new commercial activities and markets, increase the competitiveness and strengthen job growth. They make groundbreaking process, product and/or service innovations possible and are therefore relevant for science, society and market.

Yes I am interested

[Open Technology Programme 2022](#)

Title	<u>Open Technology Programme 2022</u>			
DHI pillar	NeuroTech	OncoTech	CardioTech	Integrated Tech.
Funder	NWO			
Program	Domain Applied and Engineering Sciences (AES) Open Technology Programme			
Aim of the call	Researchers from all disciplines can submit proposals for application-oriented technical-scientific research via the OTP. OTP NWO Domain AES aim of bringing about knowledge transfer between technical sciences and users. For companies and partners it offers a low-threshold way to connect with application-oriented research. This can be done by making a financial or material contribution. An application must contain a substantial proportion of research activities. Research applications are examined both for scientific quality and from			

	the perspective of knowledge utilisation. Both criteria are weighted equally in the decision-making process. An application must contain a substantial proportion of research activities; the OTP is not intended for applications that consist predominantly of investments or activities other than research.
Applicants / consortium	Full, associate and assistant professors and other researchers with a comparable position may submit an application if they have a tenured position (and therefore a paid position for an indefinite period) or a tenure track agreement. Consortium: main and co-applicants, co-funders and users. Co-applicants must play an active role in conducting the project. The (sub-)project leaders and beneficiary or beneficiaries are jointly responsible for implementation of the entire project.
Budget	Max. AES contribution per project is € 850,000 (including VAT). For projects of an investment nature (> € 150,000 in investments), the maximum AES contribution is M€ 1, including VAT. From 1 January 2022 to 15 December 2022 is € 21,000,000.
Co-funding	If the total project costs exceed € 600,000, a contribution to the project costs (co-funding) by users is required: 25% of the sum in excess of € 600,000.
Deadline	Continuous application ; The grant application period for the first package opens on 1 January 2022. The period will close once 18 applications have been accepted for consideration. This cycle will be repeated until the last such period closes on 15 December 2022.
Link	https://www.nwo.nl/en/calls/open-technology-programme-2022
Other	<ul style="list-style-type: none"> -maximum duration of the proposed project is six years -users providing co-funding must provide a letter of support to the applicant, signed by a duly authorised person within the organisation -letters of support from potential users are permitted. -resubmission: Research applications that were rejected in a previous AES selection procedure cannot be resubmitted until at least six months have passed since the date of the rejection decision.

Yes I am interested

[Early detection of cancer - innovations for detection and diagnosis' KIC Demand-driven Partnership NWO –KWF Kankerbestrijding](#)

Title	Early detection of cancer - innovations for detection and diagnosis' KIC Demand-driven Partnership NWO –KWF Kankerbestrijding			
DHI pillar	NeuroTech	OncoTech	CardioTech	Integrated Tech.
Funder	NWO-KWF			
Program	NWO Innovation Covenant (KIC) DEMAND – driven partnerships for partners			
Aim of the call	<p>The aim of this call is the development and application of innovative or even disruptive, widely accessible diagnostic possibilities for the early detection of cancer. What falls within the scope of this call (this list contains examples and is by no means exhaustive): – Research into risk stratification, use of data, artificial intelligence, genetic tests, wearables, lab-on-a-chip technology, smart forms of monitoring and other technologically innovative methods. – A test/method/marker/model that already exists for another disease that can be made suitable for oncology. – Making existing fundamental knowledge suitable for application in tests/tools for a certain section of the population. – To increase the support of acceptance of the technological innovation to be developed within society, researchers are expected to make societal aspects (such as behaviour, ethics and safety) part of the research question. The realisation of an early Health Technology Assessment (HTA) can also contribute to the increase of chances of implementation.</p> <p>The aim of this programme is to realise improvement and innovation within early detection in oncology by means of encouraging the relevant interdisciplinary collaborations in</p>			

	<p>research and development projects. Innovations that match the needs of the user: Besides technological innovation, the successful implementation of these technological developments in practice and eventually society requires that social innovation also takes place to facilitate support and acceptance. The knowledge and technology developed must be available to everybody and be usable by anybody. By involving different parties and end users, such as patients, patient associations, general practitioners, physicians and nurses, early in the process, the following questions in the area of, for example, artificial intelligence, can be better answered. How can technology be deployed in a responsible manner for the making of choices? And how can the privacy and autonomy of users be guaranteed in the process? How can optimal use of technology by care professionals be encouraged, safeguarded and/or supported? Interdisciplinary consortia: In this programme, the development and application of new technologies for the early detection of cancer, and the social and societal aspects that play a role in this, are expected to take centre stage in research proposals. A</p>
Applicants / consortium	consortium: Main applicant, Co-applicant(s), Co-funder(s), Collaborating partner(s), (external) Stakeholders
Budget	Mini. €500.000 – max. €1.250.000 can be applied for; NWO finances maximally 90% of the total project budget; the rest of the funding must be contributed by the compulsory co-funding; In total: 4.7 million euros. NWO and KWF Dutch Cancer, Society are contributing equally to this grant ceiling.
Co-funding	10% co-funding of the total project budget (in kind/in cash), of which at least € 10,000 in cash for large companies and € 5000 in cash for SMEs
Deadline	pre-proposals: 10th May, 2022 full proposals: 22 nd September, 2022
Link	https://www.nwo.nl/en/calls/early-detection-cancer-innovations-detection-and-diagnosis-kic-demand-driven-partnership-nwo?conversion_tags=
Other	<p>-it is crucial that relevant stakeholders such as patients, the Ministry of Health, Welfare and Sport, TNO, health insurers all or the National Institute for Public Health and the Environment (RIVM) are involved at as early a stage as possible.</p> <p>-KWF's objectives are to:</p> <ul style="list-style-type: none"> - Prevent cancer where we know it to be possible. - Facilitate a better treatment of all forms of cancer. - Committing to a better quality of life for (former) cancer patients and their loved ones. - Do everything possible to ensure that cancer patients are also provided with good care in the final stage of their life.

Yes I am interested

[Open Competition Domain Science - M](#)

Title	Open Competition Domain Science - M			
DHI pillar	NeuroTech	OncoTech	CardioTech	Integrated Tech.
Funder	NWO			
Program	Open Competition Domain Science - M			
Aim of the call	<p>NWO stimulates excellent, curiosity-driven disciplinary, interdisciplinary and multidisciplinary research. In doing this, NWO focuses on all scientific disciplines and the entire knowledge chain with an emphasis on fundamental research. Curiosity-driven scientific research forms the foundation for understanding the world around us, for understanding the natural and human past, and for making important new discoveries. This funding instrument is open for research proposals with a question in or overlapping the fields of earth sciences, astronomy, chemistry, computer science, life sciences, physics and</p>			

	<p>mathematics. Proposals can be monodisciplinary, multidisciplinary or interdisciplinary in nature.</p> <p>ENW has three types of funding in the Open Competition: XS, M and XL. Each type of funding has a specific aim and conditions. A promising idea can be quickly explored with XS funding and expanded further with M funding. With XL funding, it can grow into a challenging and innovative line of research in which research groups combine expertise and strengths and work together in a consortium. This call for proposals describes the options for applying for ENW-M funding. For more detailed information about the ENW-XS and ENW-XL grants we refer to the corresponding calls for proposals on the NWO website.</p> <p>ENW-M grants are intended for realising curiosity-driven scientific research of high quality. The ENW-M grant offers researchers the opportunity to elaborate original, innovative, risky ideas and to realise scientific innovations that can form the basis for the research themes of the future. There are three categories of ENW-M grants: ENW-M-1 (1 scientific position), ENW-M-2 (2 scientific positions in collaboration) and ENW-M-invest (investments) that are assessed in competition with each other. Section 3.2 states what you can apply for under the different types of grant.</p>
Applicants / consortium	<p>Full, associate and assistant professors and other researchers with a comparable position may submit an application if they have a tenured position (and therefore a paid position for an indefinite period) or a tenure track agreement.</p> <p>ENW-M-1 and ENW-M-invest have a single main applicant and no co-applicants.</p> <p>ENW-M-2 has a single main applicant and a single co-applicant who work together and whose expertise is complementary. Main applicant and co-applicant may be employed by the same organisation, as long as their expertise is complementary.</p>
Budget	<p>An ENW-M-1 grant: max. € 350,000 for a single temporary scientific position (PhD or postdoc) in combination with the other budget modules available. The module Investments (€ 150,000 to € 500,000) and the module Money follows Cooperation are not available for this type of grant.</p> <p>An ENW-M-2: max. € 700,000 for two temporary scientific positions (PhD or postdoc) in combination with the other budget modules available with the exception of the module Investments (€ 150,000 to € 500,000). The scientific positions must be equally allocated across both collaborating applicants.</p> <p>An ENW-M-invest grant: mini € 150,000 - max. € 500,000, for the funding of an investment via the module Investments (€ 150,000 to € 500,000). The other modules are not available for this type of grant.</p> <p>For the period 6 August 2021 up to and including 31 July 2022 is € 32,000,000. budget is divided among five packages of proposals, each package consists of up to 72 proposals that will complete the assessment procedure. For each package, approximately € 6,400,000 is available. From this, an amount of € 720,000 will be earmarked for at most two proposals that will be awarded funding via preferential treatment</p>
Co-funding	na
Deadline	Continuous application; There are no deadlines. The round will close as soon as the 72nd application in the fifth package has been admitted or, at the latest, by July 31, 2022
Link	https://www.nwo.nl/en/calls/open-competition-domain-science-m
Other	<ul style="list-style-type: none"> - For this Call for proposals, your application must fit in the NWO Domain Science; - Applications with a (partial) domain-overarching component shall only be considered by the NWO Domain Science if the core of the research proposal fits one or more of the seven disciplines of the Domain Science - A main applicant or co-applicant may only submit an ENW-M proposal for substantive consideration once every 12 months. -To simplify the acquisition of funding for starting researchers (= new tenured members of staff and tenure trackers early in their scientific career) they can make use of a one-off request for preferential treatment. This only applies to ENW-M-1 proposals. (see call for proposals page 7)

Yes I am interested

Open Competition Domain Science – XS (young talent!)

Title	<u>Open Competition Domain Science – XS</u>				
DHI pillar	NeuroTech	OncoTech	CardioTech	Integrated Tech.	
Funder	NWO				
Program	Open Competition Domain Science – XS				
Aim of the call	The ENW-XS category is specifically intended to encourage curiosity-driven and bold research that involves the relatively rapid exploration of a promising idea. At the end of the ENW-XS project, researchers can decide for themselves whether or not to pursue this new line of research any further. One way in which this can be done is to submit a proposal within another funding programme in the Open Competition Domain Science (ENW-M and ENW-XL) or elsewhere. Due to the emphasis on high-risk research , Domain Science will be devoting extra attention to the publication of the results of all XS projects; not only those that open up potential new lines of research, but expressly also those that do not achieve the expected results. The ENW-XS grants are intended to support promising ideas and to facilitate innovative and more speculative initiatives within the seven Domain Science disciplines. The proposed research is groundbreaking and involves a real risk of failure . What counts is that all results, be they positive or negative, must contribute to the advancement of science.				
Applicants / consortium	ENW-XS grants are available to researchers who hold a postdoctoral position that spans the entire term of the project. Researchers who have obtained a PhD and/or hold a professorial position can apply. ENW-XS proposal has a single applicant and no co-applicants.				
Budget	ENW-XS grants are available for projects with a maximum budget of €50,000. In total: €5,200,000.				
Co-funding	na				
Deadline	10 May, 2022. Decision anticipated by 7 July, 2022. 13 September, 2022. Decision anticipated by 3 November, 2022. 25 October, 2022. Decision anticipated by 8 December, 2022.				
Link	https://www.nwo.nl/en/calls/open-competition-domain-science-xs-package-22-2				
Other					

Yes I am interested

ZonMw Medicinale cannabis als behandeling bij kinderepilepsie - Medicinal cannabis as a treatment for childhood epilepsy

Title	<u>ZonMw Medicinale cannabis als behandeling bij kinderepilepsie - Medicinal cannabis as a treatment for childhood epilepsy</u>				
DHI pillar	NeuroTech	OncoTech	CardioTech	Integrated Tech.	
Funder	ZonMw				
Program	Programma: Goed Gebruik Geneesmiddelen				
Aim of the call	Based on the exploration, the Ministry of Health, Welfare and Sport has commissioned ZonMw to investigate funding with the aim of increasing knowledge about the effectiveness of medicinal cannabis for the treatment of children with treatment-resistant epilepsy. Therapy-resistant epilepsy has many negative effects on the quality of life of the child and his environment and the clinical picture high social costs. This underlines the need to conduct sound and independent effectiveness research. Research funded by ZonMw focuses on transcending societal topics that contribute to the general public interest to improve the quality, affordability and to improve the accessibility of care in the Netherlands, which are not picked up by the market, because who, for example, have no				

	<p>interest in it from a financial point of view. Market forces thus provide negative factors for society and inhibits positive factors that society can benefit from taking advantage. The results of the studies have national impact and are directly applicable in the daily clinical practice. The implementation of the results has a substantial impact on health benefits, cost savings and/or quality of care. Keywords: Pharmacotherapy, Effectiveness, medical cannabis, Epilepsy, Children</p> <p>Requirements for project:</p> <p>Hypothesis: The following hypothesis should be addressed in the research project: medicinal cannabis decreases the frequency and/or severity of seizures in treatment-resistant children epilepsy. Secondary outcome measures are quality of life, side effects and costs to be taken.</p> <ul style="list-style-type: none"> • The subsidy is awarded to a party that fulfills the requirements described hypothesis in conjunction with the secondary outcome measures in an integrated plan of approach. • The party has demonstrable relevant experience in conducting clinical research with children and the relevant indication. <p>Research product</p> <p>The product under investigation is manufactured on the basis of the raw material supplied by the Bureau of Medicinal Cannabis (BMC). This concerns dried flowers (flossing, whether or not in granulated form) as available on prescription from pharmacies or a representative extract thereof. This raw material is available in different varieties with known amounts of the active substances THC and CBD. The following requirements apply:</p> <ul style="list-style-type: none"> • You agree on the delivery of the raw material(s) and the associated costs in good time contact the BMC via info@cannabisbureau.nl. The results of this coordination are already mentioned in your subsidy application. • The preparation of the product to be tested is carried out by an authorized in Netherlands-based party. • You have an opium exemption to be able to conduct research with cannabis. <p>More information about applying for an opium exemption can be found on the website of the BMC (https://www.cannabisbureau.nl/opiumontheffing).</p>
Applicants / consortium	<p>The following party(ies) can claim (part of) the subsidy:</p> <ol style="list-style-type: none"> 1. Dutch research organisation(s) within the meaning of EU state aid law 2. Dutch healthcare institution(s) 3. Organization(s) with knowledge and expertise in (clinical) research into and treatment of (child) epilepsy <p>*please consider that TUD might not be suitable for coordination of such project, but could be a partner e.g. within CH&T consortium</p>
Budget	Max. € 1.400.000; for max. 4 years; one project will be funded
Co-funding	Third party contributions are not required, but are recommended, where possible and appropriate, to further promote implementation of the results
Deadline	19 July 2022
Link	https://www.zonmw.nl/nl/subsidies/openstaande-subsidieoproepen/detail/item/medicinale-cannabis-als-behandeling-bij-kinderepilepsie/
Other	- Informatiepagina subsidieronde Medicinale cannabis als behandeling bij kinderepilepsie -there is a "Bijlage 5 - Checklist indiening subsidieaanvraag" you need to go through (see call for proposals, page 20)

Yes I am interested

HTA methodologie - ronde 1: Methodologie voor waardebeoordeling van incrementeel ontwikkelende medische technologie (MedTech) HTA methodology - round 1: Methodology for Valuation of Incrementally Developing Medical Technology (MedTech)

Title	<u>HTA methodologie - ronde 1: Methodologie voor waardebeoordeling van incrementeel ontwikkelende medische technologie (MedTech)</u>			
DHI pillar	NeuroTech	OncoTech	CardioTech	Integrated Tech.
Funder	ZonMw			
Program	Programma: HTA Methodologie 2021-2024			
Aim of the call	<p>The aim of this call is, where there is a decision dilemma surrounding incremental developing medical technology (MedTech), to make better decision-making by stakeholder(s) possible. Your project idea should focus on a (case of a) social relevant decision dilemma surrounding incrementally developing MedTech and within this a simplify methodologically relevant problem. For this, a new methodology developed or improved an existing methodology. This new or improved methodology, after research into suitability and usability, must ultimately be possible to be applied more broadly than only for the examined decision dilemma. Ultimately, awarded projects should lead to better decisions about appropriate use, effective procurement of care and/or package management. This call is limited to the (further) development of methodology for incrementally developing medtech. Incrementally evolving is defined here as a step change or addition. We distinguish two types of incremental development, namely:</p> <ul style="list-style-type: none"> - Through further development: Incremental changes due to the further development of the medical technology. This includes technology that is expected to be constantly new versions become available. - In the application: Incremental changes in the application of medical technology (e.g. changes in the indication area, such as indication creep) that may also entail changes in effectiveness or in healthcare costs. <p>Requirements:</p> <ul style="list-style-type: none"> -Decision dilemma about incrementally developing MedTech is socially relevant -Methodology as a product -collaboration -applicable for the Netherlands -short duration of the project, max 12-24 months 			
Applicants / consortium	<p>The following party(ies) can claim (part of) the subsidy:</p> <ol style="list-style-type: none"> 1. Dutch research organisation(s) within the meaning of EU state aid law 2. Dutch healthcare institution(s) 3. Organization(s) with knowledge and expertise in (clinical) research into and treatment of (child) epilepsy <p>*please consider that TUD might not be suitable for coordination of such project, but could be a partner e.g. within CH&T consortium (e.g. with EUR)</p>			
Budget	Max. € 200.000,-; for max. 2 years; in total 5 tot 7 projects, total budget: € 1.000.000			
Co-funding	na			
Deadline	19 April 2022			
Link	https://www.zonmw.nl/nl/subsidies/openstaande-subsidieoproepen/detail/item/hta-methodologie-ronde-1-methodologie-voor-waardebeoordeling-van-incrementeel-ontwikkelende-medisch/			
Other	<p>-By MedTech we mean medical innovations in the form of products (including e-health products, such as software). This innovation can be used both inside and outside a healthcare institution used for the prevention, diagnosis, support or treatment of people. MedTech is not limited to one care domain; it can be used in curative care, the care sector and/or welfare. MedTech contains both 'low-tech' (such as surgical masks and wheelchairs) and 'high-tech' (such as MRI scanners, robots, implants and eHealth). MedTech is not in this call limited to certain classifications of risk assessment as defined in Regulation (EU) 2017/745. However, medicines and questions about organizing care are excluded from this call.</p>			

-application form is online via ZonMw portal

Yes I am interested

Pre-announcement funding round technologies to support therapy development COVID-19

ZonMw intends to open a call on the development of innovative technologies for the treatment of COVID-19. The use of these technologies is important **for a faster recovery after a COVID-19 infection**. In addition, it is important that these technologies can be used in the treatment of other infectious diseases in preparation for subsequent pandemics. Read the news item for more information. **The aim of this call is to stimulate the (further) development of (key) technologies for the discovery and development of therapies for COVID-19.** Examples of this are innovative platforms that can contribute to a broad spectrum and/or specific therapeutics and prophylactics, or experimental in vitro and in vivo models for the validation and further development of new therapies. This is necessary for unprotected groups and to quickly anticipate a new dangerous variant of the virus. In addition, it contributes to the preparation for new infectious diseases by further boosting and scaling up new promising developments.

Room for new ideas and unexpected breakthroughs: The call offers room for new ideas/insights and unexpected breakthroughs. This means that the basic and operating principles of the technology are clear when applying for a grant, but experimental evidence is still lacking (TRL 1). In the project, a proof-of-concept, method to determine the practical feasibility of a technology, is developed from this technology (TRL 3). These so-called breakthrough projects form a basis for new lines of research and collaborations in the future. We expect that some of these experimental studies will result in groundbreaking discoveries that could lead to new lines of research and solution directions with potentially large clinical impact. We also accept that this will not apply to some of the projects (“High Risk-High Gain” projects).

Multidisciplinary collaboration: With this call we lay the foundation for a multidisciplinary collaboration between medical and technological experts. These should work together in a consortium.

Criteria: The general ZonMw criteria form the basis for the criteria for relevance and quality. You will find this in the procedure brochure applicants. The call for specific relevance and quality criteria can be found in the call for subsidies. The conditions and criteria included in the published call for grants are leading. Keep an eye on the subsidy calendar for more information about this subsidy call.

Do you have questions? Please contact covid19@zonmw.nl.

More information

- [Vervolgprogramma COVID \(2021\)](#)
- [Deelprogramma behandeling COVID-19](#)
- [Onderzoek naar corona en COVID-19](#)

Link: <https://www.zonmw.nl/nl/actueel/nieuws/detail/item/vooraankondiging-subsidieronde-technologieen-ter-ondersteuning-van-therapieontwikkeling-covid-19/>

Yes I am interested

EU calls (collaborative)

JPI HDHL: “Nutrition-responsiveness of the immune system: interplay between infectious diseases and diet-related metabolic diseases and the potential for food-based solutions (NUTRIMMUNE)”

Title	<u>“Nutrition-responsiveness of the immune system: interplay between infectious diseases and diet-related metabolic diseases and the potential for food-based solutions (NUTRIMMUNE)”</u>			
DHI pillar	NeuroTech	OncoTech	CardioTech	Integrated Tech. and other
Funder	EU JPI HDHL - ZonMw			
Program	Joint Programming Initiative 'a Healthy Diet for a Healthy Life			
Aim of the call	<p>The aim of this call is to support transnational, collaborative research projects that gain a better understanding of the interactions between nutrition and immunity within the context of its interplay between infectious diseases and diet-related metabolic diseases. Relevant research questions may include (but are not limited) the generation of scientific evidence for differences in individual susceptibility to and the severity of infectious diseases in people with diet-related metabolic diseases such as obesity or type 2 diabetes. Research should focus on the underlying mechanisms by which nutrition, food composition and/or dietary patterns affect immune function (e.g. both innate and adaptive immune function, and microbiome). The roles of host genotype, body weight and composition, and life style factors such as physical fitness, and stress can also be considered. Proposals should focus on one or both of the following topics:</p> <ul style="list-style-type: none"> • Establishing the cause-and-effect relationship between nutrition, immune function and infectious diseases in the context of diet-related metabolic disorders. Building on existing knowledge to further identify mechanisms of action (including common molecular pathways), projects will: <ul style="list-style-type: none"> - Advance understanding of how nutrition, foods and dietary patterns modulate immune system homeostasis, response (e.g. inflammation), dysregulation and susceptibility to infectious disease across the life course in people with diet-related metabolic diseases. - Explore how nutrition may contribute to infectious disease risk in people with diet-related metabolic diseases at various stages including prevention of, severity of, recovery from, and rehabilitation after the infectious disease. • Development of innovative food solutions. <p>Proof of principle studies are desired in order to support the development of effective diet-related health-improvement strategies health-improvement strategies and/or food products to promote a healthy immune system in people with diet-related metabolic diseases and their application at any stage of the infectious disease process.</p>			
Applicants / consortium	<p>The following conditions apply to the composition of transnational consortia: Minimum of 3 partners from 3 different participating countries. These 3 partners should be eligible for funding by one of the participating organisations No more than 2 eligible partners can originate from the same country. Maximum of 6 eligible partners per consortium. Total size of consortium cannot exceed 8 applicants (including researchers that participate as collaborator)</p>			
Budget	<p>Dutch applicants can apply for maximum €400.000 per application (this is excl. in kind cost for the Dutch component per proposal). An additional budget of €50.000,- can be requested for coordination cost (Dutch researcher acts as coordinator of the international consort; max 4 projects will be funded</p>			

Co-funding	na
Deadline	21 April 2022
Link	https://www.healthydietforhealthylife.eu/index.php/call-activities/calls/98-calls-site- restyling/670-nutrimune-2022?jij=1648648448240
Other	NUTRIMMUNE Call Frequently Asked Questions (FAQ) Call for proposals

Yes I am interested

EIC Pathfinder Challenge: Cardiogenomics

Title	EIC Pathfinder Challenge: Cardiogenomics		
DHI pillar	NeuroTech	OncoTech	CardioTech
Funder	European Innovation Council (EIC)		
Program	Pathfinder Challenge		
Aim of the call	<p>Cardiogenomics holds the potential to address existing gaps in the diagnosis and treatment of cardiovascular diseases (CVD), which would enable better outcome for the patient. Advanced genetic testing taking into account complex inheritance, or combining genetic testing, transcriptomics, proteomics and metabolomics analysis with clinical phenotype can improve clinical management of the CVD and identify more accurately, who is likely to be at risk for major cardiovascular events such as heart failure or sudden death . Many gene variants associated with CVD are of unknown significance and thus of limited clinical utility. Our ability to sub-classify CVD diseases according to their underlying molecular mechanism has been enhanced due to technological approaches such as, spatial or single-cell transcriptomics, and others.</p> <p>The overall aim of this Challenge is to pave the way for novel therapies for major CVD conditions including hemorrhagic and ischemic stroke, aneurysm, cardiomyopathy and certain types of arrhythmias and other conditions, for which no effective treatments are currently available.</p> <p>Specific objectives</p> <ul style="list-style-type: none"> -to identify single or multiple gene variants of high biological significance or other key molecules associated with the CVDs that would allow for accurate stratification of patients and guide the physician in their clinical management and monitoring of these CVDs; -to identify novel targets based on these variants for specific CVD indication(s) that would allow for the development of first in class therapies for the same indication; -to seek for novel technological solutions that could contribute to the development and acceleration of first in class therapies for major CVD conditions for which no effective treatments are currently available. <p>Expected outcomes and impacts</p> <ul style="list-style-type: none"> -impact on the practice of cardiology: identification of pathogenic mutations or multiple variants that have actionable effects (by disrupting normal biochemical pathways associated with the cause and/or progression of the disease), will have a substantive impact on the practice of cardiology; -accelerating the implementation of personalised care in CVD: deciphering the molecular pathogenesis underlying the clinical pathology of a CVD disease, is key for implementing personalised care. Performing targeted DNA sequencing on CVD patient(s) to identify previously characterised pathogenic mutations, is expected to become part of the daily clinical routine in the CVD clinics. Targeted genetic testing is envisaged to serve a triple purpose: <ul style="list-style-type: none"> --to achieve an early and more accurate diagnosis; --to guide the physician to administer the right treatment for the right patient (personalised treatment); and --to predict more accurately post treatment clinical course (favorable or non- clinical prognosis). 		

	<p>-gathering the necessary knowledge and data that would enable to apply disease modelling for CVD, including through 3D in-vitro models, to be used for screening drugs/therapies for CVDs.</p> <p>Specific conditions</p> <p>Applicants must convincingly demonstrate that they have access to a large cohort of genomic and/or transcriptomics and/or proteomics and/or metabolomics database from CVD patients.</p>
Applicants / consortium	Consortia of at least three different independent legal entities ¹⁴ established in at least three different eligible countries. *OR single applicants or small consortia (two partners).
Budget	4 mln/ project; in total 167 mln (for all 6 challenges)
Co-funding	na
Deadline	19 October 2022
Link	https://eic.ec.europa.eu/eic-funding-opportunities/calls-proposals/eic-pathfinder-challenge-cardiogenomics_en
Other	*please consider that this is not a good option for TUD to apply as single applicant

Yes I am interested

[EIC Pathfinder Challenge: Towards the Healthcare Continuum: technologies to support a radical shift from episodic to continuous healthcare](#)

Title	EIC Pathfinder Challenge: Towards the Healthcare Continuum: technologies to support a radical shift from episodic to continuous healthcare			
DHI pillar	NeuroTech	OncoTech	CardioTech	Integrated Tech.
Funder	European Innovation Council (EIC)			
Program	Pathfinder Challenge			
Aim of the call	<p>Today, episodic (symptom-triggered) healthcare remains the norm. To a large extent, individuals are entrusted with the responsibility to self-monitor and trigger requests to the health system upon identification of relevant symptoms. In spite of the growing number of screening programmes, the diagnosis of a vast majority of disorders, including those in which early action has a direct impact on morbidity or survival, still relies heavily on the individual to initiate the process. Further, a substantial fraction of outpatients manage the post-treatment phase, particularly of non-life threatening conditions, with qualitative self-monitoring, seeking help only upon perceived evidence of disease recurrence. In essence the current approach to healthcare is mostly reactive. Technology can support much needed progress towards continuous and preventive healthcare, in which individuals are accompanied continuously and unobtrusively by health monitoring technology and practitioners, proactively offering diagnosis, treatment or follow up at the optimal pace and with the optimal protocol as dictated by clinical evidence. However, the full potential of the continuous healthcare model has not been fully realised as, for most conditions, diagnostic technologies do not exist with the required attributes: unobtrusiveness (environment-embedded, body-embedded, object-embedded, home-integrated, etc.), clinical grade reliability, affordability, etc. For example, faulting-free on-skin, under-skin or implantable bio-sensors for long-term use, new modalities for Volatile Organic Compound (VOC) sensing (breathomics), new personal imaging systems e.g. THz-based or optoacoustic, unobtrusive continuous gut microbiome monitoring, etc. still require substantial groundwork. The objective of this EIC Pathfinder Challenge is to develop systems and technologies starting at very low TRL for unobtrusive monitoring of human health with new continuous and personal imaging and sensing modalities, implementing continuous assessment, processing and analysis of the data to identify early signs of disease.</p> <p>This call can support innovative technologies ranging from the sensor level up to the system level for effective integration of multimodal data. Proposals can aim at monitoring</p>			

	<p>a family of conditions or a wider mix of health factors, using the optimal combination of single-point or historic multi-point sensor data and, if appropriate, clinical records, genomic data, etc. to realise maximal performance.</p> <p>Involvement of relevant stakeholders (e.g., clinical experts and patient organizations) from an early stage is recommended.</p> <p>The gender dimension in research content should be considered, where relevant as well as the involvement of relevant stakeholders (e.g. clinical practitioners, patient organisations, etc.) from an early stage.</p> <p>Specific objectives</p> <ul style="list-style-type: none"> • develop a novel technology (device, instrument or full system) for unobtrusive proactive healthcare. The targeted technology should offer life-long health status monitoring and elements of predictive medicine with methodologies grounded in existing scientific evidence; • the end objective must be a Proof-of-Concept and preliminary data suggestive of adequate safety and performance, while paying attention to minimising false positives that could hamper its real-world use; • the targeted technology should make the case for a clinically acceptable solution amenable to successful evaluation under common Health Technology Assessment (HTA) methodologies; • the path to future integration in the European healthcare workflow, specifically in relation to the inter-operability with existing infrastructures, as well as take up and compliance by appropriate patient populations, should be plausible. <p>Expected outcomes and impacts</p> <p>The expected impact should be the establishment of the basis for the transformation of the prevailing episodic, symptom-triggered, healthcare system into continuous healthcare, in which individuals are accompanied continuously and unobtrusively by health monitoring technology and practitioners, proactively offering diagnosis and treatment.</p>
Applicants / consortium	Consortia of at least three different independent legal entities ¹⁴ established in at least three different eligible countries. *OR single applicants or small consortia (two partners).
Budget	4 mln/ project; in total 167 mln (for all 6 challenges)
Co-funding	na
Deadline	19 October 2022
Link	https://eic.ec.europa.eu/eic-funding-opportunities/calls-proposals/eic-pathfinder-challenge-towards-healthcare-continuum-technologies-support-radical-shift-episodic_en
Other	*please consider that this is not a good option for TUD to apply as single applicant

Yes I am interested

Foundations providing research funding

Name	Currently open call?	DHI pillar / focus
Brain Foundation (Hersenstichting)	No, follow the website	neurotech
Epilepsy Foundation	No, follow the website	neurotech
Hanarth Fonds , Artificial Intelligence in Oncology	Hanarth Fonds Fellowship , open until 27 May 2022 Research project, open next year	oncotech
Nationaal Fonds tegen Kanker (NFtK)	mensgerichte behandeling zoals voeding, beweging, en welzijn binnen de oncologische zorg, open until 1 June 2022	oncotech
ReumaNederland	Talent programma: Het Junior en Senior Talent programma, open until 1 March 2023 Explore programma: LangLopende Programmalijnen, open until 1 November 2022 Focus programma: Thema gedreven, open until 15 June 2022	reumatische aandoeningen
Hartstichting	No, follow the website	cardiotech
Nierstichting	Creativiteit, Junior / Senior Talent en Succes Aanjager beurzen, vooraanvragen 1 april 2022 - 16 mei 2022	nierziekten

Yes I am interested